<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">19</article-id><article-id pub-id-type="doi">10.17816/psaic19</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Transplantation of neuronal precursors derived from induced pluripotent stem cells into the striatum of rats with the toxin-induced model of Huntington’s disease</article-title><trans-title-group xml:lang="ru"><trans-title>Трансплантация нейрональных предшественников, полученных из индуцированных плюрипотентных стволовых клеток, в стриатум крыс с токсической моделью болезни Гентингтона</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stavrovskaya</surname><given-names>Alla V.</given-names></name><name xml:lang="ru"><surname>Ставровская</surname><given-names>Алла Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yamshchikova</surname><given-names>Nina G.</given-names></name><name xml:lang="ru"><surname>Ямщикова</surname><given-names>Нина Гавриловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ol'shansky</surname><given-names>Аrtyem S.</given-names></name><name xml:lang="ru"><surname>Ольшанский</surname><given-names>Артем Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Konovalova</surname><given-names>Eugeniya V.</given-names></name><name xml:lang="ru"><surname>Коновалова</surname><given-names>Евгения В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2704-6282</contrib-id><name-alternatives><name xml:lang="en"><surname>Illarioshkin</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Иллариошкин</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Corr. Member of the Russian Academy of Sciences, Deputy Director, Head, Department for brain research</p></bio><bio xml:lang="ru"><p>д.м.н., проф., член-корр. РАН, зам. директора по научной работе, рук. отдела исследований мозга</p></bio><email>alla_stav@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-12-02" publication-format="electronic"><day>02</day><month>12</month><year>2016</year></pub-date><volume>10</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>39</fpage><lpage>44</lpage><history><date date-type="received" iso-8601-date="2017-01-30"><day>30</day><month>01</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Stavrovskaya A.V., Yamshchikova N.G., Ol’shanskiy A.S., Konovalova E.V., Illarioshkin S.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Stavrovskaya A.V., Yamshchikova N.G., Ol’shanskiy A.S., Konovalova E.V., Illarioshkin S.N.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Stavrovskaya A.V., Yamshchikova N.G., Ol’shanskiy A.S., Konovalova E.V., Illarioshkin S.N.</copyright-holder><copyright-holder xml:lang="ru">Stavrovskaya A.V., Yamshchikova N.G., Ol’shanskiy A.S., Konovalova E.V., Illarioshkin S.N.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/19">https://annaly-nevrologii.com/pathID/article/view/19</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Huntington’s disease (HD) is a severe neurodegenerative disorder characterized by choreic hyperkinesis, cognitive decline, behavioral disorders, and progressive neuronal death, mostly in the striatum. Since HD is a fatal disorder, searching for efficient treatment methods, including those based on cell replacement therapy, is quite relevant. The experimental models of HD are used increasingly often.The <bold>objective</bold> of the study was to assess effectiveness and safety of transplantation of neuronal precursors differentiated from induced pluripotent stem cells (iPSCs) from a healthy donor into the striatum of rats with 3-NPA-induced HD model.<bold>Materials and methods</bold>. We studied the influence of neurotransplantation on the behavioral effects in rats with HD model induced by intrastriatal injection of 3-nitropropiotic acid (3-NPA). In the study group of animals (n=11), human neuronal precursors derived from iPSCs of a healthy volunteer were transplanted into the caudate nuclei (5×105 per 5 μl of normal saline solution bilaterally); the control group of animals (n=10) received normal saline solution. The animals were tested using the Any-maze video tracking system; the parameters of the open-field test and the conditioned avoidance response test were evaluated.<bold>Results.</bold> An analysis of behavioral effects after transplantation demonstrated that introduction of neuronal iPSC derivatives into the caudate nuclei of rats with induced HD model was accompanied by recovery of motor activity of the animals (horizontal and vertical), as opposed to the control group. It was found during testing the reproducibility of the conditioned avoidance responses that the conditioned avoidance responses in control animals were weakened, whereas intrastriatal transplantation of neurons abruptly increased the latency of moving into the dark compartment of the chamber in the conditioned avoidance response test.<bold>Conclusions.</bold> The pilot experiment using the HD model showed that neurotransplantation using iPSC derivatives recovers the reduced motor activity in rats and improves memory trace keeping, which contributes to correction of motor and cognitive disorders induced by 3-NPA neurotoxin.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Болезнь Гентингтона (БГ) – тяжелое нейродегенеративное заболевание, характеризующееся хореическим гиперкинезом, снижением когнитивных функций, поведенческими расстройствами и прогрессирующей гибелью нейронов, прежде всего, в стриатуме. В силу фатального характера БГ актуальным является поиск эффективных методов ее лечения, в т.ч. на основе заместительного клеточного подхода, для чего все шире используются экспериментальные модели данного заболевания.<bold>Цель работы</bold> – оценка эффективности и безопасности трансплантации в стриатум крыс с 3-НПК-индуцированной моделью БГ нейрональных предшественников, дифференцированных из индуцированных плюрипотентных стволовых клеток (ИПСК) здорового донора.<bold>Материалы и методы.</bold> Исследовано влияние нейротрансплантации на поведенческие эффекты крыс с моделью БГ, вызванной интрастриатным введением 3-нитропропионовой кислоты (3-НПК). В основной группе животных (n=11) в качестве трансплантируемого материала в хвостатые ядра вводили человеческие нейрональные предшественники ( 5×10 5 в 5 мкл физиологического раствора билатерально), полученные из ИПСК здорового донора; в контрольной группе (n=10) – физиологический раствор. Тестирование животных проводилось с помощью системы видеонаблюдения Any-maze; оценивались показатели двигательной активности в «открытом поле» и условные реакции пассивного избегания (УРПИ).<bold>Результаты.</bold> Анализ поведенческих эффектов после трансплантации показал, что введение нейрональных ИПСК-производных в хвостатые ядра крыс с моделью БГ сопровождалось восстановлением горизонтальной и вертикальной двигательной активности животных, чего не наблюдалось в контроле. При тестировании воспроизведения реакций пассивного избегания было обнаружено, что у контрольных животных условные реакции избегания были ослаблены, тогда как интрастриатное введение нейронов привело к резкому возрастанию величины латентного периода перехода (ЛП) в темный отсек камеры УРПИ.<bold>Заключение.</bold> По данным проведенного пилотного эксперимента на модели БГ, нейротрансплантация с использованием производных ИПСК позволяет восстановить сниженную двигательную активность крыс и улучшить сохранение памятного следа, что способствует коррекции двигательных и когнитивных нарушений, вызванных нейротоксином 3-НПК.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Hungtington’s disease</kwd><kwd>3-nitropropionic acid</kwd><kwd>behavior and memory disorders</kwd><kwd>striatum</kwd><kwd>neurotransplantation</kwd><kwd>induced pluripotent stem cells</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>болезнь Гентингтона</kwd><kwd>3-нитропропионовая кислота</kwd><kwd>нарушения поведения и памяти</kwd><kwd>стриатум</kwd><kwd>нейротрансплантация</kwd><kwd>индуцированные плюрипотентные стволовые клетки</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993; 72: 971–983. PMID: 8458085.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ivanova-Smolenskaya I.A., Ovchinnikov I.V., Illarioshkin S.N. et al., [Molecular and genetic testing in diagnostics of sporadic cases of Huntington’s chorea]. Zhurnal nevrologii b psihiatrii im.Korsakova) 1998; 3: 19–22.(in Russ.).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Illarioshkin S.N. [DNA diagnostics and medicogenetic consultation]. Moscow; МIA, 2004. (in Russ.).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Estrada Sanchez A.M., Mejia-Toiber J., Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch. Med. Res. 2008; 39: 265–276. PMID: 18279698 DOI: 10.1016/j.arcmed.2007.11.011.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ivanova-Smolenskaya I.A., Markova E.D., Illarioshkin S.N., Nikol’skaya N.N. [Monogenic hereditary diseases of the central nervous system] In: Vel’tishcheva J.E., Temina P.A. Nasledstvennye bolezni nervnoy sistemy. Rukovodstvo dlya vrachey (eds). [Hereditary diseases of nervous system. Guidelines for doctors]. Moscow: Meditsina, 1998: 9–104. (in Russ.).</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Illarioshkin S.N. Huntington’s disease as model for studying of neurodegenerative diseases. [Byulleten natsional’ogo obshchestva po izucheniyu bolezni Parkinsona i rasstroystvam dvizheniy] 2016; 1: 3–11.(in Russ.).</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Southwell A.L., Ko J., Patterson P.H. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J. Neurosci. 2009; 29: 13589–13602. PMID: 19864571 DOI: 10.1523/JNEUROSCI.4286-09.2009.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Nekrasov E.D., Lebedeva O.S., Vasina E.M. et al. [Platform for studying of Huntington’s disease on the base of induced pluripotent stem cells]. Annaly klinicheskoi I eksperimentalnoi nevrologii. 2012; 4: 30–35. (in Russ.).</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bachoud-Levi A.-C. Neural grafts in Huntington’s disease: Viability after 10 years. Lancet Neurol. 2009; 8: 979-981. PMID: 19833293 DOI: 10.1016/S1474-4422(09)70278-9.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Cicchetti F., Saporta S., Hauser R.A. et al. Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. USA. 2009; 106: 12483–12488. PMID: 19620721 DOI: 10.1073/pnas.0904239106.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kerkis I., Haddad M., Valverde C., Glosman S. Neural and mesenchymal stem cells in animal models of Huntington’s disease: past experiences and future challenges. Stem Cell Research &amp; Therapy. 2015; 6: 232. PMID: 26667114 DOI: 10.1186/s13287-015-0248-1.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Maucksch C., Vazey E., Gordon R., Connor B. Stem cell-based therapy for Huntington’s disease. J. Cell. Biochem. 2013; 114: 754–763. PMID: 23097329 DOI: 10.1002/jcb.24432.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Reuter I., Tai Y.F., Pavese N. et al. Long-term clinical and positron emission tomography out-come of fetal striatal transplantation in Huntington’s disease. J. Neurol. Neurosurg. Psychiatry. 2008; 79: 948–951.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663–676. PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yamanaka S., Blau H.M. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010; 465: 704–712. PMID: 20535199 DOI: 10.1038/nature09229.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Fink K., Crane A. et al., Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington’s disease. Stem Cells Translational Medicine. 2014; 3: 620–631. PMID: 24657963 DOI: 10.5966/sctm.2013-0151.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Fink K., Rossignol J., Lu M. et al. Survival and differentiation of adenovirus-generated induced pluripotent stem cells transplanted into the rat striatum. Cell Transplant. 2013 [Epub ahead of print]. PMID: 23879897 DOI: 10.3727/096368913X670958.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Peng J., Zeng X. The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. Stem Cell Res. Ther. 2011; 2: 32. PMID: 21861938 DOI: 10.1186/scrt73.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Stavrovskaya A.V., Konorova I.L., Illarioshkin S.N. et al., [Technologies of nervous system diseases modeling]. M.A. Piradov, S.N. Illarioshkin, M.M. Tanashyan (eds). Nevrologiya XXI veka: diagnosticheskie, lechebnye i issledovatel’skie tekhnologii: Rukovodstvo dlya vrachey. V 3-kh t. T. 3: Sovremennye issledovatel’skie tekhnologii v eksperimental’noy nevrologii. [Neurology of the 21st century: diagnostic, medical and research technologies: Guidelines for doctors in 3 Vol. Vol.3: The modern research technologies in the experimental neurology]. Мoscow: «АТМО», 2015: 73–133. (in Russ.).</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Cisbani G, Cicchetti F. An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity. Cell Death Dis. 2012; 3: e382. PMID: 22932724 DOI: 10.1038/cddis.2012.121.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Roberts T.J., Price J., Williams S.C., Modo M. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington’s disease. Neuroscience. 2006; 139: 1187–1199. PMID: 16517087 DOI:10.1016/j.neuroscience.2006.01.025.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ryu J.K., Kim J., Cho S.J. et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol. Dis. 2004; 16: 68–77. PMID: 15207263 DOI: 10.1016/j.nbd.2004.01.016.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Tunez I., Tasset I., Perez De La Cruz V. et al. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington’s disease: Past, present and future. Molecules. 2010; 15: 878–916. PMID: 20335954 DOI: 10.3390/molecules15020878.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>El Massioui N., Ouary S., Cheruel F. et al. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp. Neurol. 2001; 172: 172–181. PMID: 11681849 DOI: 10.1006/exnr.2001.7766.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Paxinos G., Watson C. The rat brain in stereotaxic coordinates. Academic Press, 1998.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Stavrovskaya A.V., Voronkov D.N., Yamshikova N.G. et al. [Experience of the experimental modeling of Huntington’s disease]. Annaly klinicheskoi I neksperimentalnoi nevrologii. 2015; 3: 49–55.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Bantubungi K., Blum D., Cuvelier L. et al. Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington’s disease. Mol. Cell Neurosci. 2008; 37: 454–470. PMID: 18083596 DOI: 10.1016/j.mcn.2007.11.001.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Johann V., Schiefer J., Sass C. et al. Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington’s disease. Exp Brain Res. 2007; 177: 458–470. PMID: 17013619 DOI: 10.1007/s00221-006-0689-y.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Lee S.T., Chu K., Park J.E. et al. Intravenous administration of human neural stem cells induces functional recovery in Huntington’s disease rat model. Neurosci. Res. 2005; 52: 243–249. PMID: 15896865 DOI: 10.1016/j.neures.2005.03.016.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Shear D.A., Haik K.L., Dunbar G.L. Creatine reduces 3-nitropropionic-acid-induced cogni- tive and motor abnormalities in rats. Neuroreport. 2000; 11: 1833–1837. PMID: 10884028.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Rossignol J., Boyer C., Lévèque X. et al. Mesenchymal stem cell transplantation and DMEM administration in a 3-NP rat model of Huntington’s disease: Morphological and behavioral outcomes. Behav. Brain Res. 2011; 217: 369–378. PMID: 21070819 DOI: 10.1016/j.bbr.2010.11.006.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kendall A., Hantraye P., Palfi S. Striatal tissue transplantation in non-human primates. Prog. Brain Res. 2000; 127: 381–404. PMID: 11142037.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. J. Neurochem. 2005; 95: 1521–1540. PMID: 16300642 DOI: 10.1111/j.1471-4159.2005.03515.x.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Becker S., Lim J. A computational model of prefrontal control in free recall: strategic memory use in the California Verbal Learning Task. J. Cogn. Neurosci. 2003; 15: 821–832. PMID: 14511535 DOI:10.1162/089892903322370744.</mixed-citation></ref></ref-list></back></article>
